+1 858-523-8231
Login | Register
menu
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
1395347-24-6,MFCD30533398
Catalog No.:AA01EO2J

1395347-24-6 | ISA-2011B

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
100%
1 week  
$170.00   $119.00
- +
5mg
100%
1 week  
$388.00   $272.00
- +
10mg
100%
1 week  
$586.00   $410.00
- +
25mg
100%
1 week  
$964.00   $675.00
- +
50mg
100%
1 week  
$1,349.00   $944.00
- +
100mg
100%
1 week  
$1,795.00   $1,256.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA01EO2J
Chemical Name:
ISA-2011B
CAS Number:
1395347-24-6
Molecular Formula:
C22H18ClN3O4
Molecular Weight:
423.8490
MDL Number:
MFCD30533398
SMILES:
Clc1ccc2c(c1)c(c[nH]2)[C@H]1N2C(=O)CN(C(=O)[C@@H]2Cc2c1cc1OCOc1c2)C
Properties
Computed Properties
 
Complexity:
737  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
2  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
30  
Hydrogen Bond Acceptor Count:
4  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0  
Rotatable Bond Count:
1  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
2.9  

Literature

Title: The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America 20140902

Title: Exploiting the PI3K/AKT pathway for cancer drug discovery.

Journal: Nature reviews. Drug discovery 20051201

Title: BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity.

Journal: Immunity 20031101

Title: Type I phosphatidylinositol-4-phosphate 5-kinases are distinct members of this novel lipid kinase family.

Journal: The Journal of biological chemistry 19961220

Title: Semenas J, et al. The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3689-98.

Title: Sarwar M, et al. Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes MDV3100 resistance in prostate cancer cells. Oncotarget. 2016 Sep 27;7(39):63065-63081.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
Submit
SDS
Related Products of 1395347-24-6
Building Blocks
More >
Tags:1395347-24-6 Molecular Formula|1395347-24-6 MDL|1395347-24-6 SMILES|1395347-24-6 ISA-2011B
Catalog No.: AA01EO2J
1395347-24-6,MFCD30533398
1395347-24-6 | ISA-2011B
Pack Size： 1mg
Purity： 100%
1 week
$170.00 $119.00
Pack Size： 5mg
Purity： 100%
1 week
$388.00 $272.00
Pack Size： 10mg
Purity： 100%
1 week
$586.00 $410.00
Pack Size： 25mg
Purity： 100%
1 week
$964.00 $675.00
Pack Size： 50mg
Purity： 100%
1 week
$1,349.00 $944.00
Pack Size： 100mg
Purity： 100%
1 week
$1,795.00 $1,256.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA01EO2J
Chemical Name: ISA-2011B
CAS Number: 1395347-24-6
Molecular Formula: C22H18ClN3O4
Molecular Weight: 423.8490
MDL Number: MFCD30533398
SMILES: Clc1ccc2c(c1)c(c[nH]2)[C@H]1N2C(=O)CN(C(=O)[C@@H]2Cc2c1cc1OCOc1c2)C
Properties
Complexity: 737  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 2  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 30  
Hydrogen Bond Acceptor Count: 4  
Hydrogen Bond Donor Count: 1  
Isotope Atom Count: 0  
Rotatable Bond Count: 1  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 2.9  
Literature fold

Title: The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America20140902

Title: Exploiting the PI3K/AKT pathway for cancer drug discovery.

Journal: Nature reviews. Drug discovery20051201

Title: BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity.

Journal: Immunity20031101

Title: Type I phosphatidylinositol-4-phosphate 5-kinases are distinct members of this novel lipid kinase family.

Journal: The Journal of biological chemistry19961220

Title: Semenas J, et al. The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3689-98.

Title: Sarwar M, et al. Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes MDV3100 resistance in prostate cancer cells. Oncotarget. 2016 Sep 27;7(39):63065-63081.

Related Products of of 1395347-24-6
Building Blocks More >
943540-74-7
943540-74-7
JNJ-38877618
AA01EO61 | MFCD31657377
315705-75-0
315705-75-0
JNJ0966
AA01EOCM | MFCD02045222
1240516-71-5
1240516-71-5
GSK2239633A
AA01EOI8 | MFCD30533311
1699750-95-2
1699750-95-2
EOAI3402143
AA01EONH | MFCD31692368
1427325-95-8
1427325-95-8
(1-(4-fluoropentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone
AA01EOUG
1776086-02-2
1776086-02-2
1-(5-fluoropentyl)-N-(phenylmethyl)-1H-indole-3-carboxamide
AA01EP3F | MFCD31380151
114784-59-7
114784-59-7
3,4,4aS,5,16aR,17,18,19-octahydro-21,22,26-trimethoxy-4,17-dimethyl-16H-1,24:6,9-dietheno-11,15-metheno-2H-pyrido[2’,3’:17,18][1,11]dioxacycloeicosino[2,3,4-ij]isoquinolin-12-ol-4-nitrobenzoate
AA01EPCP
67579-76-4
67579-76-4
trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide
AA01EPJN
1071703-97-3
1071703-97-3
N-[1-[2-(4-methylphenyl)ethyl]-4-piperidinyl]-N-phenyl-propanamide,monohydrochloride
AA01EPP7
135662-06-5
135662-06-5
1-(2,4-dinitrophenyl)-L-prolyl-L-tyrosyl-L-alanyl-L-tyrosyl-L-tryptophyl-L-methionyl-L-arginine,trifluoroacetatesalt
AA01EPVU
Submit
© 2017 AA BLOCKS, INC. All rights reserved.